Evidence and Research

Trials have shown that daily oral PrEP works if taken correctly and consistently. But there’s still a lot to learn about how to deliver oral PrEP.

The safety and efficacy of daily oral tenofovir-based PrEP is well-established. Policy and program decisions are guided by both data from the original randomized clinical trials as well as newer studies. Demonstration projects, implementation initiatives and national rollout provide information about challenges and opportunities with oral PrEP delivery, and can help optimize services and identify gaps.

Read below to find out more about:

Clinical Trials Evidence

The 2012 US FDA decision and WHO guidance on PrEP demonstration projects were based on data from randomized controlled trials of tenofovir-based PrEP. Additional randomized trials since then have added to this evidence base.

As more countries approve daily oral PrEP for prevention (visit AVAC’s Global PrEP Tracker for the latest) and begin to scale up national PrEP programs, there are opportunities to understand how services may be optimized and adapted. Already, many of these programs have provided valuable lessons.

PrEP Watch was created and is maintained by AVAC, a non-profit organization based in New York that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of new and emerging HIV prevention options as part of a comprehensive response to the HIV/AIDS pandemic. AVAC receives no money from pharmaceutical companies, including Gilead Sciences. If you have a comment or suggestion regarding the content of this site, click here to contact us. Read our privacy policy.